Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA approves Jemperli to treat dMMR-related endometrial cancer

By Brian Buntz | February 10, 2023

GSKFDA has approved Jemperli from GSK (NYSE:GSK) for adult patients with mismatch repair-deficient or advanced endometrial carcinoma (dMMR).

GSK predicts Jemperli will generate peak sales of $1.4 billion to $2.8 million.

The drug is indicated for adults with dMMR-related or advanced endometrial carcinoma who have progressed after a previous platinum-containing regimen. This drug is not suitable for those who need curative surgery or radiation.

Approved based on a Phase 1 study

The FDA approved the drug based on data from GARNET Phase 1, in which it had a 45.4% overall response rate. The single-arm, multicenter, open-label study of Jemperli monotherapy showed that 85.9% of patients experienced a response within 12 months. 54.7% had a response lasting at least 24 months.

Data from the ongoing GARNET trial’s A1 cohort supported Jemperli’s approval. This trial evaluated Jemperli as a monotherapy in patients with advanced solid tumors. The drug was assessed in the A1 cohort of 141 patients suffering from advanced or recurrent endometrial carcinomas that had progressed after prior platinum-containing treatment.

Jemperli monotherapy is being evaluated in advanced solid tumors as part of the ongoing GARNET Phase 1 study.

Jemperli (dostarlimab-gxly), a programmed-death receptor-1 (PD-1)-blocking antibody, binds to the PD-1 receptor. It then blocks its interaction with the PD-1 ligands PD-1L1 and PD-1L2.

Endometrial cancer is common

A 2020 BMJ article states that women with advanced or recurrent endometrial cancer (EC) are often limited in their treatment options and have poor outcomes. This paper presented the results of Phase 2 studies of durvalumab in women with advanced, mismatch repair-deficient or repair-proficient endometrial carcinoma. Durvalumab, also known as Imfinzi, is not currently approved for endometrial cancer.

Globally, endometrial cancer is one of the most prevalent gynecologic cancers. In 2018, there were 382,069 new endometrial canver (EC) cases and 89,929 deaths.

GSK estimates that each year, there are 417,000 new cases worldwide. According to GSK, the incidence of this type of cancer will increase by nearly 40% by 2040.


Filed Under: Oncology
Tagged With: Jemperli
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
AP Biosciences charts course for safer CD137 bispecifics with its T-cube platform
Cellares and UW-Madison partner to automate manufacturing for novel solid tumor CAR-T
Why smaller, simpler molecular glues are gaining attention in drug discovery
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE